Global Information
회사소개 | 문의 | 비교리스트

세계의 항생제 시장(2019-2029년)

Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others

리서치사 Visiongain Ltd
발행일 2019년 04월 상품 코드 226947
페이지 정보 영문 297 Pages
가격
£ 3,499 ₩ 5,331,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 5,940,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 7,616,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 10,663,000 PDF (Global License - Includes Free Datasets)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 항생제 시장(2019-2029년) Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others
발행일 : 2019년 04월 페이지 정보 : 영문 297 Pages

세계의 항생제(Antibacterial Drugs) 시장은 2018년에 430억 달러에 달했습니다. 시장은 향후 5년간 CAGR(연평균 성장률)로 2%의 성장이 예측됩니다.

세계의 항생제 시장에 대해 조사분석했으며, 시장 예측, 2차 시장 예측, 주요 출시약의 매출 예측, 주요 선진국·신흥 국가·지역별 시장의 매출 예측, R&D 파이프라인, 주요 기업 등에 관한 정보를 정리하여 전해드립니다.

제1장 리포트 개요

제2장 항생제 소개

  • 세균 감염의 종류
  • 감염증을 일으키는 주요 세균
  • 일반적인 세균 감염의 발생률과 사망률
  • 감염증의 치료
    • 항생제 개발의 역사
    • 작용기서
    • 주요 약제 클래스
    • 항생제 내성

제3장 항생제 : 세계 시장

  • 항생제 매출은 안정기에 진입
  • 항균제 : 시장 세분화
  • 항생제 시장의 예측 : Fluoroquinolones의 매출 감소
  • 시장 촉진요인·억제요인
  • 제네릭 의약품의 감소와 처방전 관리가 시장 성장을 저지
  • Pfizer가 시장 리더
  • 단편적 시장이 보다 세분화

제4장 세팔로스포린 시장 예측

  • 세팔로스포린 시장의 현황 : 지배적 브랜드의 부재
    • 후기 단계의 세팔로스포린이 향후 시장 점유율을 확대
    • Basilea, Merc, Actavis, AstraZeneca가 주도
    • 시장 촉진요인·억제요인
    • 시장 우선권이 없는 세팔로스포린
    • 새로운 세팔로스포린의 강력한 파이프라인
    • Rocephin(Roche) : 미국의 유일한 임질 치료법
    • Sulperazon : 인도 호흡기 감염증(RTI)·요로감염증(UTI)의 대표적인 치료법
    • Zinnat/Ceftin : GSK의 기성 세팔로스포린
    • Meiact : 다양한 시중 감염증용 항생제
    • Flomox : Shionogi의 제3세대 세팔로스포린
    • Zinforo/Teflaro(Ceftaroline Fosamil) : 최초의 제5세대 세팔로스포린
    • Zeftera(Ceftobiprole) : 유럽에서 폐렴 치료제로서 인증
    • CXA-201(Ceftrolozane-Tazobactam) : 차기 블록버스터 항생제
    • CAZ-AVI(Ceftazidime-Avibactam) : 승인

제5장 페니실린 시장 예측

  • 제네릭 의약품과 Augmentin이 시장을 독점
  • 페니실린의 시장 점유율 : Augmentin은 향후 10년간 독점적 지위를 상실
  • 페니실린의 시장 규모 전망
  • 시장 촉진요인·억제요인
  • Augmentin : 제네릭 의약품과의 경쟁에 직면하는 블록버스터 의약품
  • Zosyn/Tazocin(Piperacillin-Tazobactam) : 폐렴 치료제
  • Unasyn : 그람음성균/양성균용 항생제
  • Amoxil(Amoxicillin) : 역사적인 항생제 브랜드
  • Amoxicillin 제네릭 의약품
  • 클라뷰란산 : Amoxicillin의 제네릭 의약품

제6장 플루오로퀴놀론 시장 예측

  • 플루오로퀴놀론 시장
  • 시장 점유율의 변화
  • 플루오로퀴놀론 항생제 : 시장 예측
  • 시장 동향
  • 시장 예측
  • Avelox
  • Cravit/Levaquin(levofloxacin)
  • Vigamox
  • Cirpodex·Cipro : Ciprofloxacin의 2종류 조제약
  • Geninax
  • Baxdela(delafloxacin)

제7장 마크로라이드 시장 예측

  • 마크로라이드 시장
  • 시장 점유율의 변화
  • 마크로라이드 항생제 : 시장 예측
  • 시장 동향
  • Biaxin/Clarith
  • Zithromax
  • Dalacin
  • Dificid
  • Solithera(solithromycin)

제8장 카바페넴 시장 예측

  • 카바페넴 시장
  • 시장 점유율의 변화
  • 카바페넴 항생제 : 시장 예측
  • 시장 동향
  • Merrem/Meropenem
  • Primaxin
  • Invanz
  • Doribax

제9장 기타 항생제 시장 예측

  • 기타 약제 클래스 시장
  • 시장 점유율의 변화
  • 기타 항생제 : 시장 예측
  • 시장 동향
  • Zyvox : 대표적인 항생제
  • Cubicin : ABSSSI의 대표적 브랜드
  • Tygacil : 많은 적응증에 대해 인증된 테트라사이클린
  • TOBI/TOBI Podhaler : 낭포성 섬유증의 대표적인 흡입기
  • Solodyn : 중증 여드름의 치료제
  • Vibativ : 신규 Lipoglycopeptide의 제한적 가능성
  • Sirturo : 다제내성 TB(결핵)용 새로운 옵션
  • Tedizolid : Zyvox를 잇는 대표적 의약품이 되는가?
  • Oritavancin : 새로운 PK 프로파일 포함 항생제
  • Dalvance(dalbavancin) : 적응증 시장에서의 치열한 경쟁
  • Surotomycin : 클로스트리듐 디피실(C. difficile) 치료제
  • Nemonoxacin : 대만의 세계 시장용 항생제

제10장 세계의 항생제 시장 : 지역별

  • 북미의 항생제 시장 : 부문별
  • 유럽의 항생제 시장 : 부문별
  • 아시아태평양의 항생제 시장 : 부문별
  • 기타 지역의 항생제 시장 : 부문별

제11장 주요 국가 시장

  • 미국과 중국이 시장을 독점
  • 미국의 평균 이상 시장 성장 : 지역별 예측
  • 중국의 시장 점유율 정체, 브라질과 인도의 점유율 확대 전망
  • 감염증의 발생률 : 국가별
  • 항생제의 소비 : 국가별
  • 미국의 항생제 시장
  • EU : 세계 2위 시장
  • 일본 : 여전히 세계 4위
  • 한국 : 항생제 이용 수준은 앞으로도 높은가?
  • BRIC 국가 : 새로운 확대 전망
  • 중국 : 항생제 과다 사용에 의한 시장 확대
  • 인도 : 향후 10년간 50% 확대 전망
  • 브라질 : 2배로 증가할 전망
  • 러시아 : TB 유행에 의한 시장 성장 전망

제12장 항생제 시장의 주요 기업

  • Pfizer Inc.
  • Novartis AG
  • Merck & Co. Inc.
  • GlaxoSmithKline PLC
  • BioVersys AG
  • AstraZeneca PLC
  • Allecra Therapeutics GmbH
  • Adenium Biotech ApS
  • Bayer AG
  • Eli Lilly and Company

제13장 항생제의 R&D 파이프라인 검증

  • 그람양성 vs.그람음성
  • 파이프라인은 소분자약이 우세
  • 제I상 주요 후보의약품
  • 제II상 주요 후보의약품
  • 제III상 주요 후보의약품

제14장 항생제 산업·시장의 정성 분석

  • SWOT 분석
  • STEP 분석
  • 시장의 성숙화와 강력한 수요 전망
  • 세계의 높은 감염증 유병률
  • 세계의 항생제에 대한 수요
  • 감염증의 동물 모델 : 기타 치료 영역에 비해 높은 예측성
  • 포화 시장으로의 참여
  • 제네릭 의약품에 대한 우위성 등

제15장 항생제 시장 : 결론

부록

KSA 19.06.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 2.1: Common Bacterial Infections and Their Causes
  • Table 2.2: Details of the ESKAPE Bacteria
  • Table 2.3: Leading Causes of Infectious Diseases Deaths Worldwide, 2010
  • Table 2.4: Mechanisms of Action for Antibacterial Drugs
  • Table 3.1: Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2013-2018
  • Table 3.2: Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2018
  • Table 3.3: Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2019-2029
  • Table 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2018-2029
  • Table 3.5: Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2018
  • Table 4.1: Leading Branded Cephalosporin Antibacterial Drugs: Important Facts, 2018
  • Table 4.2: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2018
  • Table 4.3: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2021
  • Table 4.4: Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2029
  • Table 4.5: Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.6: Cephalosporin Market Forecast by Product: Market Share (%), 2018-2029
  • Table 4.7: Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.8: Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.9: Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.10: Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.11: Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.12: Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
  • Table 4.13: Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.14: Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.15: Zerbraxa Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.16: Zavicefta Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.1: Leading Branded Penicillin Drugs: Important Facts
  • Table 5.2: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2018
  • Table 5.3: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2019
  • Table 5.4: Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2029
  • Table 5.5: Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.6: Penicillin Market Forecast by Product: Market Share (%), 2019-2029
  • Table 5.7: Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.8: Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.9: Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.10: Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.11: Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 5.12: Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.1: Leading Branded Fluoroquinolone Drugs: Important Facts
  • Table 6.2: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2018
  • Table 6.3: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2019
  • Table 6.4: Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2029
  • Table 6.5: Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.6: Fluoroquinolone Market Forecast by Product: Market Share (%), 2018-2029
  • Table 6.7: Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.8: Generic Manufacturers of Levofloxacin, 2017
  • Table 6.9: Cravit/Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.10: Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.11: Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.12: Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.13: Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.14: Baxdxela Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.1: Leading Branded Macrolides: Important Facts
  • Table 7.2: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2018
  • Table 7.3: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2019
  • Table 7.4: Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2029
  • Table 7.5: Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.6: Macrolide Market Forecast by Product: Market Shares (%), 2019-2029
  • Table 7.7: Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.8: Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.9: Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.10: Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.11: Solithera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.1: Leading Branded Carbapenems: Important Facts
  • Table 8.2: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2018
  • Table 8.3: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2019
  • Table 8.4: Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2029
  • Table 8.5: Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.6: Carbapenem Market Forecast by Product: Market Share (%), 2019-2029
  • Table 8.7: Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.8: Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.9: Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.10: Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.1: Other Leading Branded Antibacterials: Important Facts
  • Table 9.2: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2018
  • Table 9.3: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2019
  • Table 9.4: Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2029
  • Table 9.5: Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.6: Other Agents: Market Forecast by Product - Market Share (%), 2018-2029
  • Table 9.7: Oxazolidinones in Mid to Late Stage Clinical Development, 2017
  • Table 9.8: Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.9: Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.10: Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.11: TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.12: Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.13: Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.14: Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.15: Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.16: Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.17: Dalvance Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.18: Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 9.19: Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 10.1: Antibacterial Drug Sales by Regions: Market Size ($bn) and Share (%), 2018
  • Table 10.2: North America Antibacterial Drug Sales, 2018-2029
  • Table 10.3: Europe Antibacterial Drug Sales, 2018-2029
  • Table 10.4: Asia-Pacific Antibacterial Drug Sales, 2018-2029
  • Table 10.5: Rest-of-the-World Antibacterial Drug Sales, 2018-2029
  • Table 11.1: Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2018
  • Table 11.2: Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2019-2029
  • Table 11.3: Antibacterial Drug Markets: National and Regional Market Shares (%), 2018-2029
  • Table 11.4: Incidence of Pneumonia in National Markets, 2016
  • Table 11.5: Incidence of Community Acquired Urinary Tract Infections in National Markets, 2016
  • Table 11.6: Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2016
  • Table 11.7: Incidence of Upper Respiratory Tract Infections in National Markets, 2016
  • Table 11.8: Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
  • Table 11.9: Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
  • Table 11.10: US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.11: EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.12: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.13: French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.14: German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.15: UK Early Stage Antibacterial Drug Developers, 2016
  • Table 11.16: UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.17: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.18: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.19: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.20: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.21: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.22: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.23: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 11.24: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 12.1: Pfizer Inc. Recent Financials, 2015-2017
  • Table 12.2: Pfizer Inc. Recent Financials, 2015-2017
  • Table 12.3: Novartis AG: Pipeline Portfolio
  • Table 12.4: Novartis AG: Developments
  • Table 12.5: Merck & Co. Inc.: Product Portfolio
  • Table 12.6: Merck & Co. Inc.: Developments
  • Table 12.7: Merck & Co. Inc.: Product Portfolio
  • Table 12.8: GlaxoSmithKline PLC: Developments
  • Table 12.9: BioVersys AG: Pipeline Portfolio
  • Table 12.10: BioVersys AG: Pipeline Portfolio
  • Table 12.11: AstraZeneca PLC: Product Portfolio
  • Table 12.12: AstraZeneca PLC: Developments
  • Table 12.13: Allecra Therapeutics GmbH: Pipeline Portfolio
  • Table 12.14: Allecra Therapeutics GmbH: Developments
  • Table 12.15: Adenium Biotech ApS: Pipeline Portfolio
  • Table 12.16: Bayer AG Product Portfolio
  • Table 12.17: Eli Lilly and Company: Recent Financials, 2015-2017
  • Table 13.1: Antibacterial Drug Candidates in Phase I Development, 2018
  • Table 13.2: Antibacterial Drug Candidates in Other Drug Development Phase, 2018
  • Table 13.3: Antibacterial Drug Candidates in Phase II Development, 2018
  • Table 13.4: Antibacterial Drug Candidates in Phase III Development, 2018
  • Table 14.1: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2019-2029
  • Table 14.2: Bacterial Related Funding for BARDA, 2011-2014
  • Table 15.1: World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2019, 2021, 2024, and 2029

List of Figures

  • Figure 2.1: Leading Causes of Infectious Disease Deaths Worldwide, 2010
  • Figure 2.2: Key Events in the History of Antibacterial Drug Development
  • Figure 3.1: Historic Global Market Size ($bn), 2013-2017
  • Figure 3.2: Global Antibacterial Drug Market by Sector: Market Share (%), 2018
  • Figure 3.3: Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2019-2029
  • Figure 3.4: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2019
  • Figure 3.5: Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2029
  • Figure 3.6: Leading Branded Antibacterial Manufacturers: Market Share (%), 2018
  • Figure 4.1: Cephalosporin Market by Product: Market Share (%), 2018
  • Figure 4.2: Cephalosporin Market by Product: Market Share (%), 2021
  • Figure 4.3: Cephalosporin Market by Product: Market Share (%), 2029
  • Figure 4.4: Cephalosporin Market Forecast: Revenue ($bn), 2019-2029
  • Figure 4.5: Cephalosporin Market: Drivers and Restraints, 2019-2029
  • Figure 4.6: Rocephin Forecast: Revenue ($bn), 2019-2029
  • Figure 4.7: Sulperazon Forecast: Revenue ($bn), 2019-2029
  • Figure 4.8: Zinnat/Ceftin Forecast: Revenue ($bn), 2019-2029
  • Figure 4.9: Meiact Forecast: Revenue ($bn), 2019-2029
  • Figure 4.10: Flomox Forecast: Revenue ($bn), 2019-2029
  • Figure 4.11: Zinforo/Teflaro Forecast: Revenue ($bn), 2019-2029
  • Figure 4.12: Zeftera Forecast: Revenue ($bn), 2019-2029
  • Figure 4.13: Zerbraxa Forecast: Revenue ($bn), 2019-2029
  • Figure 4.14: Zavicefta Forecast: Revenue ($bn), 2019-2029
  • Figure 5.1 Penicillin Market by Product: Market Share (%), 2018
  • Figure 5.2 Penicillin Market by Product: Market Share (%), 2019
  • Figure 5.3 Penicillin Market by Product: Market Share (%), 2029
  • Figure 5.4 Penicillin Market Forecast: Revenue ($bn), 2019-2029
  • Figure 5.5 Augmentin Forecast: Revenue ($bn), 2019-2029
  • Figure 5.6 Zosyn/Tazocin Forecast: Revenue ($bn), 2019-2029
  • Figure 5.7 Unasyn Forecast: Revenue ($bn), 2019-2029
  • Figure 5.8 Amoxil Forecast: Revenue ($bn), 2019-2029
  • Figure 5.9 Generic Amoxicillin Forecast: Revenue ($bn), 2019-2029
  • Figure 5.10 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2019-2029
  • Figure 6.1: Fluoroquinolone Market by Product: Market Share (%), 2018
  • Figure 6.2: Fluoroquinolone Market by Product: Market Share (%), 2019
  • Figure 6.3: Fluoroquinolone Market by Product: Market Share (%), 2029
  • Figure 6.4: Fluoroquinolone Market Forecast: Revenue ($bn), 2019-2029
  • Figure 6.5: Avelox Forecast: Revenue ($bn), 2019-2029
  • Figure 6.6: Cravit/Levaquin Forecast: Revenue ($bn), 2019-2029
  • Figure 6.7: Vigamox Forecast: Revenue ($bn), 2019-2029
  • Figure 6.8: Ciprodex Forecast: Revenue ($bn), 2019-2029
  • Figure 6.9: Cipro/Ciprobay Forecast: Revenue ($bn), 2019-2029
  • Figure 6.10: Geninax Forecast: Revenue ($bn), 2019-2029
  • Figure 6.11: Baxdela Forecast: Revenue ($bn), 2019-2029
  • Figure 7.1: Macrolide Market by Product: Market Share (%), 2018
  • Figure 7.2: Macrolide Market by Product: Market Share (%), 2019
  • Figure 7.3: Macrolide Market by Product: Market Share (%), 2029
  • Figure 7.4: Macrolide Market Forecast: Revenue ($bn), 2019-2029
  • Figure 7.5: Biaxin/Clarith Forecast: Revenue ($bn), 2019-2029
  • Figure 7.6: Zithromax Forecast: Revenue ($bn), 2019-2029
  • Figure 7.7: Dalacin Forecast: Revenue ($bn), 2019-2029
  • Figure 7.8: Dificid Forecast: Revenue ($bn), 2019-2029
  • Figure 7.9: Solithera Forecast: Revenue ($bn), 2019-2029
  • Figure 8.1: Carbapenem Market by Product: Market Share (%), 2018
  • Figure 8.2: Carbapenem Market by Product: Market Share (%), 2019
  • Figure 8.3: Carbapenem Market by Product: Market Share (%), 2029
  • Figure 8.4: Carbapenem Market Forecast: Revenue ($bn), 2019-2029
  • Figure 8.5: Merrem Forecast: Revenue ($bn), 2019-2029
  • Figure 8.6: Primaxin Forecast: Revenue ($bn), 2019-2029
  • Figure 8.7: Invanz Forecast: Revenue ($bn), 2019-2029
  • Figure 8.8: Doribax Forecast: Revenue ($bn), 2019-2029
  • Figure 9.1: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2018
  • Figure 9.2: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2019
  • Figure 9.3: Other Classes of Antibacterial Drugs by Product: Market Share (%), 2029
  • Figure 9.4: Other Agents Market Forecast by Product: Revenue ($bn), 2019-2029
  • Figure 9.5: Zyvox Forecast: Revenue ($bn), 2019-2029
  • Figure 9.6: Cubicin Forecast: Revenue ($bn), 2019-2029
  • Figure 9.7: Tygacil Forecast: Revenue ($bn), 2019-2029
  • Figure 9.8: TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2019-2029
  • Figure 9.9: Solodyn Forecast: Revenue ($bn), 2019-2029
  • Figure 9.10: Vibativ Forecast: Revenue ($bn), 2019-2029
  • Figure 9.11: Sirturo Forecast: Revenue ($bn), 2019-2029
  • Figure 9.12: Tedizolid Forecast: Revenue ($bn), 2019-2029
  • Figure 9.13: Oritavancin Forecast: Revenue ($bn), 2019-2029
  • Figure 9.14: Dalvance Forecast: Revenue ($bn), 2019-2029
  • Figure 9.15: Surotomycin Forecast: Revenue ($bn), 2019-2029
  • Figure 9.16: Nemonoxacin Forecast: Revenue ($bn), 2019-2029
  • Figure 10.1: Global Antibacterial Drug Sales by Regions: Market Share (%), 2018
  • Figure 11.1: Antibacterial Drug Sales by National and Regional Markets: Market Share (%), 2018
  • Figure 11.2: Antibacterial Drug Market Forecasts: National and Regional Market Sizes ($bn), 2019-2029
  • Figure 11.3: Absolute Annual Antibacterial Drug Consumption by Nation, 2016
  • Figure 11.4: Per Capita Antibacterial Drug Consumption by Nation, 2016
  • Figure 11.5: US Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.6: EU Antibacterial Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2019-2029
  • Figure 11.7: Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.8: French Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.9: German Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.10: UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.11: Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.12: Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.13: South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.14: Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), 2019-2029
  • Figure 11.15: Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.16: Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.17: Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 11.18: Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029
  • Figure 12.1: Pfizer Inc. Recent Financials, 2015-2017
  • Figure 12.2: Novartis AG: Recent Financials, 2015-2017
  • Figure 12.3: Merck & Co. Inc. Recent Financials, 2015-2017
  • Figure 12.4: GlaxoSmithKline PLC: Recent Financials, 2015-2017
  • Figure 12.5: AstraZeneca PLC: Recent Financials, 2015-2017
  • Figure 12.6: Bayer AG: Recent Financials, 2015-2017
  • Figure 12.7: Eli Lilly and Company: Recent Financials, 2015-2017
  • Figure 14.1: Strengths and Weaknesses of the Antibacterial Drug Market, 2019-2029
  • Figure 14.2: Opportunities and Threats for the Antibacterial Drug Market, 2019-2029
  • Figure 14.3: Strategies and Technologies to Prevent Hospital Acquired Infections, 2018

COMPANIES LISTED:

  • Abbott Laboratories
  • AbbVie
  • Achaogen
  • Actavis
  • Actelion
  • Affinium Pharmaceutical
  • AiCuris GmbH & Co. KG
  • Alcon
  • Alkem Laboratories
  • Allergan
  • Allied Pharma
  • Apotex
  • APP Pharmaceuticals
  • Aptalis Pharma
  • Aquapharm Biodiscovery
  • Aradigm
  • Aridis Pharmaceuticals
  • Ascend Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Pharmaceuticals
  • Basilea Pharmaceuticals
  • Bayer Laboratories
  • Biomax Biotechnics
  • Bristol-Myers Squibb
  • Cadila Healthcare
  • Calixa Therapeutics
  • Cardeas Pharma
  • Cellceutix
  • Cempra Pharmaceuticals
  • Cipla
  • Claris Lifesciences
  • Cornerstone Biopharma
  • Cornerstone Therapeutics
  • Corona Remedies
  • Critical Therapeutics
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Discuva
  • Dr. Reddy's Laboratories
  • Durata Therapeutics
  • Eli Lilly
  • Emcure Pharmaceuticals
  • Eros Pharma
  • Forest Laboratories
  • Furiex Pharmaceuticals
  • Gate Pharma
  • Gilead Sciences
  • Glenmark
  • GlycoVaxyn
  • GlaxoSmithKline (GSK)
  • Hetero
  • Hi-Tech Pharma
  • Hikma Farmaceutica
  • Hospira
  • Insmed
  • Intercell
  • Itochu Chemical Frontier
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • KaloBios
  • Kenta Biotech
  • Kuhnil Pharm
  • Lupin
  • Macleod Pharmaceuticals
  • Medicis
  • MedImmune
  • Meiji
  • Melinta Therapeutics
  • Merck & Co.
  • Merlion Pharmaceuticals
  • Microlabs
  • MicuRx Pharmaceuticals
  • Mpex Pharmaceuticals
  • Mylan
  • Nabriva Therapeutics
  • Nalneva
  • Neiss Labs
  • Nektar Therapeutics
  • Novacta Biosystems
  • Novartis
  • Novexel
  • Optimer Biotechnology
  • Orchid Chemicals
  • Orchid Healthcare
  • Ortho-McNeil
  • Paratek Pharmaceuticals
  • Peninsula Pharmaceuticals
  • Pfizer
  • Pharmacia
  • Phico Therapeutics
  • Piramal Healthcare
  • Plenus Pharmaceuticals
  • Pliva
  • Polyphor
  • Procarta Biosystems
  • Procter & Gamble Pharmaceuticals
  • Ranbaxy
  • Redx Pharma
  • Roche
  • Roxane
  • R-Pharma
  • Sagent Pharmaceuticals
  • Sandoz
  • Sanofi
  • Savara Pharmaceuticals
  • Sawai Pharmaceutical
  • Schering Plough
  • Seika Pharma
  • Sequella
  • Shanghai MengKe Pharmaceuticals
  • Shionogi
  • Shire
  • Sidmak Labs
  • Solitaire Pharmacia
  • Specialised Therapeutics Australia
  • Sunovion Pharma
  • TaiGen Biotechnology
  • Taisho Toyama
  • Takeda
  • TAP Holdings
  • Targanta Therapeutics
  • Tetraphase Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theravance
  • Torrent Pharmaceuticals
  • Trius Therapeutics
  • TTY Biopharma
  • Unichem Laboratories
  • Valeant Pharmaceuticals
  • Vansen Pharma
  • ViroPharma
  • Warner Chilcott
  • Watson
  • Wockhardt
  • Zhejiang Medicine Company
  • Zuellig Pharma
  • Zydus Pharmaceuticals

List of Organisations Mentioned in the Report:

  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Duke University
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA)
  • Ministry of Health, Labour and Welfare (MHLW)
  • Michigan State University
  • National Institute for Health and Clinical Excellence (NICE)
  • National Institutes of Health (NIH)
  • University of Connecticut
  • World Health Organization (WHO)

The global antibacterial drugs market is estimated to have reach $43bn in 2018 and is expected to grow at a CAGR of 2% in the first half of the forecast period. The Cephalosporins submarket held 28% of the global antibacterial drugs market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 297-page report you will receive 144 tables and 105 figures - all unavailable elsewhere.

The 297-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Antibacterial Drugs Market forecasts from 2019-2029

Revenue forecasts for the 6 leading submarkets from 2019-2029:

  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Others

Revenue forecasts for the 43 leading marketed antibacterial drugs from 2019-2029:

  • Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
  • Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
  • Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
  • Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
  • Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
  • Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin

Revenue forecasts for the leading regional markets forecasted in this report are the following:

  • North America
  • Europe
  • Asia-Pacific
  • RoW

Each regional market is further segmented by the 6 leading submarkets.

Revenue forecasts for the leading national markets forecasted in this report are the following:

  • The US
  • Japan
  • Italy
  • France
  • The UK
  • Spain
  • Germany
  • China
  • India
  • Brazil
  • Russia
  • South Korea

This report discusses the selected leading companies:

  • Adenium Biotech ApS,
  • Allecra Therapeutics GmbH
  • AstraZeneca
  • Bayer
  • BioVersys AG
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Novartis
  • Pfizer
  • Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market
  • Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development - see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Key Questions Answered by this Report:

  • Gain forecasts from 2019 to 2029 for the overall world market and its leading submarkets, as well as those for prominent national markets.
  • Explore the regulatory landscape for leading regional and national markets, as well as expected developments for the period 2019-2029.
  • Identify drug development trends that will affect market participants from 2019 to 2029. This report contains SWOT and STEP analysis for the forecast period.
  • See discussions of companies developing, manufacturing and marketing antibiotics, exploring products, technologies, R&D, partnerships, M&A and outlooks.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Antibacterial Drugs Market. You find data, trends and predictions.

Buy our report today Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analysis
  • 1.5. Who is This Study For?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions(FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Antibacterial Drugs

  • 2.1. Types of Bacterial Infection
  • 2.2. Main Bacteria Causing Infections in Human Beings
  • 2.3. Incidence and Mortality Profiles for Common Bacterial Infection
  • 2.4. Treating Infections
    • 2.4.1. The History of Antibacterial Drug Development
    • 2.4.2. Mechanisms of Action
    • 2.4.3. Leading Classes of Antibacterial Medicines
      • 2.4.3.1. Cephalosporins
      • 2.4.3.2. Penicillins
      • 2.4.3.3. Carbapenems
      • 2.4.3.4. Fluoroquinolones
      • 2.4.3.5. Macrolides
    • 2.4.4. Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market 2019-2029

  • 3.1. Antibacterial Drugs Revenues Plateau between 2013 and 2018
  • 3.2. Antibacterial Agents-Market Segmentation
  • 3.3. Antibacterial Drugs Market Forecast 2019-2029: Decline in Revenues for Fluoroquinolones
  • 3.4. Drivers and Restraints in the Antibacterial Drugs Market, 2019-2029
  • 3.5. Generic Erosion and Prescription Control Will Limit Market Growth
  • 3.6. Changes in that Industry Sector's Market Shares, 2019-2029
  • 3.7. Pfizer is the Leader in the Antibacterial Drugs Market, 2018
  • 3.8. Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast 2019-2029

  • 4.1. Cephalosporins Market 2018-No Dominant Brands
    • 4.1.1. Late-Stage Cephalosporins to Gain Market Share Between 2019 and 2029
    • 4.1.2. Basilea, Merck, Actavis and AstraZeneca to Lead the Cephalosporins Market Between 2019 and 2029
    • 4.1.3. Drivers and Restraints on the Cephalosporins Market, 2019-2029
    • 4.1.4. Cephalosporins Lack Market Exclusivity
    • 4.1.5. Strong Pipeline for Novel Cephalosporins
    • 4.1.6. Rocephin(Roche)-The Only Treatment for Gonorrhoea in the US
      • 4.1.6.1. Off Patent but Still Effective
      • 4.1.6.2. Declining Revenues Owing to Competition-Forecast 2019-2029
    • 4.1.7. Sulperazon-India's Leading Treatment for RTIs and UTIs
      • 4.1.7.1. Continued Growth in the Emerging Markets, Revenue Forecast 2019-2029
    • 4.1.8. Zinnat/Ceftin-GSK's Established Cephalosporin
      • 4.1.8.1. Continued Decline in Revenue-Forecast 2019-2029
    • 4.1.9. Meiact-A Broad Range Community Antibiotic
      • 4.1.9.1. Spectracef Sales in the US Leads to Pass the Product
      • 4.1.9.2. Competition in Japan to Hinder Growth-Revenue Forecast 2019-2029
    • 4.1.10. Flomox-Shionogi's Third-Generation Cephalosporin
      • 4.1.10.1. Patent Issues and Litigation
      • 4.1.10.2. Genericization and Safety to Restrict Sales-Forecast 2019-2029
    • 4.1.11. Zinforo/Teflaro(ceftaroline fosamil): The First of the Fifth- Generation Cephalosporins
      • 4.1.11.1. Unmet Needs in Pneumonia to Drive Growth-Revenue Forecast 2019-2029
    • 4.1.12. Zeftera(ceftobiprole): Approved for Pneumonia in Europe
      • 4.1.12.1. Future Sales Dictated by US Approval-Revenue Forecast 2019-2029
    • 4.1.13. CXA-201(Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
      • 4.1.13.1. Broad Label and Spectrum of Activity Leads to Rapid Uptake-Revenue Forecast 2019-2029
    • 4.1.14. Zavicefta(CAZ-AVI)(Ceftazidime-Avibactam): Approved in 2015
      • 4.1.14.1. Competition from Zebraxa will Limit Sales of Zavicefta-Forecast 2019-2029

5. Penicillins Market Forecast 2019-2029

  • 5.1. Generics and Augmentin Dominate the Penicillins Market in 2018
  • 5.2. Augmentin to Lose its Dominance over the Coming 10 Years-Market Shares for Penicillin Drugs, 2019-2029
  • 5.3. Penicillin Antibacterial Drugs: Market Forecast 2019-2029
  • 5.4. Drivers and Restraints for the Penicillin Market 2019-2029
  • 5.5. Augmentin-Blockbuster Facing Generic Competition
    • 5.5.1. Augmentin-Challenges in Some Countries
    • 5.5.2. Stable Revenues Regardless of Generic Competition
    • 5.5.3. Revenue Forecast 2019-2029
  • 5.6. Zosyn/Tazocin(Piperacillin-Tazobactam)-Pneumonia Therapeutic
    • 5.6.1. Patent Expiry and Revenue Extension for Pfizer
    • 5.6.2. Historic and Current Revenue Performance
    • 5.6.3. Revenue Forecast 2019-2029
  • 5.7. Unasyn-Gram-negative and Positive Antibiotic
    • 5.7.1. Falling Revenues-Forecast 2019-2029
  • 5.8. Amoxil(Amoxicillin)-A Historic Antibacterial Brand
    • 5.8.1. Marginal Decline in Revenue-Forecast 2019-2029
  • 5.9. Generic Amoxicillin
    • 5.9.1. Revenue Forecast 2019-2029
  • 5.10. Generic Amoxicillin-Clavulanic Acid
    • 5.10.1. Revenue Forecast 2019-2029

6. Fluoroquinolones Market Forecast 2019-2029

  • 6.1. The Fluoroquinolone Market 2018
  • 6.2. Changing Market Share for Fluoroquinolone Antibacterial Drugs, 2019-2029
  • 6.3. Fluoroquinolone Antibacterial Drugs: Market Forecast 2019-2029
  • 6.4. Trends in the Fluoroquinolone Market
    • 6.4.1. Safety Fears for Fluoroquinolones
    • 6.4.2. Avelox Patent Cliff
    • 6.4.3. Inhaled Fluoroquinolone Formulations
  • 6.5. Fluoroquinolone Market Forecast 2019-2029
  • 6.6. Avelox
    • 6.6.1. Safety Profile Hampers Sales
    • 6.6.2. Generic Competition
    • 6.6.3. Revenue Forecast 2019-2029
  • 6.7. Cravit/Levaquin(levofloxacin)
    • 6.7.1. Generic Competition Affecting Revenue Worldwide
    • 6.7.2. Lifecycle Management for Cravit and Levaquin
    • 6.7.3. Revenue Forecast 2019-2029
  • 6.8. Vigamox
    • 6.8.1. Vigamox: Branded and Generic Challenges
    • 6.8.2. Moxeza: A Next-Generation Form of Vigamox
    • 6.8.3. Revenue Forecast 2019-2029
  • 6.9. Ciprodex and Cipro-two Preparations of ciprofloxacin
    • 6.9.1. Ciprodex: A Second-Generation Ophthalmic Antibiotic
      • 6.9.1.1. Revenue Forecast 2019-2029
    • 6.9.2. Cirpo Revenue Forecast 2019-2029: Continued Generic Erosion
  • 6.10. Geninax
    • 6.10.1. Revenue Forecast 2019-2029
  • 6.11. Baxdela(delafloxacin)
    • 6.11.1. Revenue Forecast 2019-2029

7. Macrolides Market Forecast 2019-2029

  • 7.1. Macrolide Market in 2018
  • 7.2. Changing Market Share for Macrolides, 2019-2029
  • 7.3. Macrolide Antibacterial Drugs: Market Forecast 2019-2029
  • 7.4. Trends in the Macrolide Market
  • 7.5. Biaxin/Clarith
    • 7.5.1. Past Revenue 2011-2015
    • 7.5.2. Lifecycle Management for Continued Market Presence
    • 7.5.3. Revenue Forecast 2019-2029
  • 7.6. Zithromax
    • 7.6.1. Concerns over Safety and Marketing in the US
    • 7.6.2. Effectiveness in Drug-Resistant Strains
    • 7.6.3. Revenue Forecast 2019-2029
  • 7.7. Dalacin
    • 7.7.1. Revenue Forecast 2019-2029
  • 7.8. Dificid
    • 7.8.1. Rapid Uptake Slowed by High Cost
    • 7.8.2. New Approvals and Expanded Indications
    • 7.8.3. Revenue Forecast 2019-2029
  • 7.9. Solithera(solithromycin)
    • 7.9.1. Revenue Forecast 2019-2029

8. Carbapenems Market Forecast 2019-2029

  • 8.1. Carbapenem Market 2018
  • 8.2. Changing Market Share for Carbapenems, 2019-2029
  • 8.3. Carbapenem Antibacterial Drugs: Market Forecast 2019-2029
  • 8.4. Trends in the Carbapenem Market
    • 8.4.1. Rising Prevalence of Carbapenemases and β-Lactamases
    • 8.4.2. No New Carbapenems in Late-Stage Trials
  • 8.5. Merrem/Meropenem
    • 8.5.1. Generics Affecting Revenue Worldwide
    • 8.5.2. Revenue Forecast 2019-2029
  • 8.6. Primaxin
    • 8.6.1. Combination Therapy for Lifecycle Management
    • 8.6.2. Historic and Current Revenues
    • 8.6.3. Revenue Forecast 2019-2029
  • 8.7. Invanz
    • 8.7.1. Revenue Forecast 2019-2029
  • 8.8. Doribax
    • 8.8.1. Doribax in HAP and VAP
    • 8.8.2. Lifecycle Management in Japan and the Rest of the World
    • 8.8.3. Revenue Forecast 2019-2029

9. Other Antibacterial Drugs Forecast, 2019-2029

  • 9.1. The Market for Other Classes of Antibacterial Drugs
  • 9.2. Changing Market Share for Fluoroquinolone Antibacterials 2019-2029
  • 9.3. Other Antibacterials: Market Forecast 2019-2029
  • 9.4. Trends in the Other Classes of Antibacterial Drugs
    • 9.4.1. New Oxazolidinones Will Drive Growth
    • 9.4.2. New Drug Classes to Drive Submarket Growth to 2029
  • 9.5. Zyvox-The Market Leading Antibacterial
    • 9.5.1. MRSA Activity Driving Revenue Growth
    • 9.5.2. Promise in Tuberculosis and Anthrax
    • 9.5.3. Patents, Litigation, and Competition-When and Who Will Produce Generic Linezolid?
    • 9.5.4. Flat Growth to Patent Expiry, Revenue Forecast 2019-2029
  • 9.6. Cubicin-The Leading Brand for ABSSSIs
    • 9.6.1. Revenue Boosted by Approvals Worldwide
    • 9.6.2. Patents, Litigation and Deals-How Long Will Market Exclusivity Last?
    • 9.6.3. Sustained Growth through to 2021, Revenue Forecast 2019-2029
  • 9.7. Tygacil-A Tetracycline with Many Approved Indications
    • 9.7.1. Concerns Limiting Revenue Potential
    • 9.7.2. Competition from Other Therapies Restricts Growth: Revenue Forecast 2019-2029
  • 9.8. TOBI/TOBI Podhaler-The Market Leading Inhaler for Cystic Fibrosis
    • 9.8.1. Historic and Current Revenue Performance
    • 9.8.2. Approvals and Launches in New Markets to Drive Revenue Growth
    • 9.8.3. Competition to Limit Long-term Growth, Revenue Forecast 2019-2029
  • 9.9. Solodyn-A Treatment for Severe Acne
    • 9.9.1. Generic Competition and Lifecycle Management
    • 9.9.2. Limited Potential for Dermatology, Revenue Forecast 2019-2029
  • 9.10. Vibativ-Limited Potential for Novel Lipoglycopeptide
    • 9.10.1. Astellas Ends its Collaboration with Theravance
    • 9.10.2. Limited HAP Label in the US-Revenue Forecast 2019-2029
  • 9.11. Sirturo-A New Option for Multi-Drug Resistant TB
    • 9.11.1. Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2019-2029
  • 9.12. Tedizolid-Market Leading Follow-on to Zyvox?
    • 9.12.1. Competition Increasing: Revenue Forecast 2019-2029
  • 9.13. Oritavancin-An Antibiotic with a Novel PK Profile
    • 9.13.1. Single Dose Differentiation to Deliver Market Share(%), Revenue Forecast 2019-2029
  • 9.14. Dalvance(dalbavancin)-Competing in a Crowded Indication
    • 9.14.1. Sustained Growth Over the Coming 10 Years, Revenue Forecast 2019-2029
  • 9.15. Surotomycin -Treatment for C. difficile
    • 9.15.1. Delayed Launch to Limit Potential, Revenue Forecast 2019-2029
  • 9.16. Nemonoxacin-Taiwan's Global Antibacterial Drug
    • 9.16.1. Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2019-2029

10. Global Anti-Bacterial Drugs Market by Region 2019-2029

  • 10.1. North America Antibacterial Drugs Market, by Sector 2019-2029
  • 10.2. Europe Antibacterial Drugs Market, by Sector 2019-2029
  • 10.3. Asia-Pacific Antibacterial Drugs Market, by Sector 2019-2029
  • 10.4. Rest-of-the-World Antibacterial Drugs Market, by Sector 2019-2029

11. The Leading National Markets 2019-2029

  • 11.1. US and China Dominate the Global Antibacterial Market
  • 11.2. Above-Average Growth in US: Regional Forecasts 2019-2029
  • 11.3. China to Slump in Market Share, While Brazil and India Push on
  • 11.4. Incidence of Infection by Country, 2016
    • 11.4.1. Incidence of Pneumonia in National Markets-Pneumonia Predominant in America
    • 11.4.2. Incidence of Community Acquired Urinary Tract Infections in National Markets-High Incidence Rates in the UK, US and Spain
    • 11.4.3. Incidence of Bacterial Skin and Skin Structure Infections in National Markets-High Potential in the US
    • 11.4.4. Incidence of Upper Respiratory Tract Infections in National Markets-Europe Leads the Way
  • 11.5. Antibacterial Drug Consumption by Country, 2016
    • 11.5.1. Antibacterial Drug Consumption in the Major National Markets
    • 11.5.2. Antibacterial Drug Consumption in Some Other National Markets
  • 11.6. The Antibacterials Market in the US
    • 11.6.1. Continued Dominance of the US Market
  • 11.7. The European Union Forms Second Largest Regional Market
    • 11.7.1. Marginal Expansion in Antibacterial Spending-Market Forecast 2019-2029
    • 11.7.2. Action to Encourage Antibacterial Drug Development in the EU
    • 11.7.3. Italy Continues to Lead the Way in Antibiotic Use
    • 11.7.4. The French Fascination with Expensive Antibacterial Drugs
    • 11.7.5. Germany-Europe's Antibiotic Steward
    • 11.7.6. Rising Use of Antibacterials Drugs in the UK
    • 11.7.7. Spanish Antibacterials Market to Expand from 2021 to 2027
  • 11.8. Japan-Still the Fourth Largest National Market
    • 11.8.1. The Pause before Growth in the Japanese Market
  • 11.9. Will South Korea Continue Its High Use of Antibiotics?
  • 11.10. BRIC Nation Sales Still Expanding-Market Forecast 2019-2029
  • 11.11. Chinese Antibacterial Market Bloated by Reported Overuse
    • 11.11.1. Developing Antibacterials in China, for China
    • 11.11.2. Governmental Controls Subdue Recent Growth-Market Forecast 2019-2029
  • 11.12. Indian Market to Expand by 50% Over the Forecast Period
    • 11.12.1. Restricting Antibiotic Use in India
    • 11.12.2. Sustained Expansion of the Indian Market, Forecast 2019-2029
  • 11.13. Brazilian Antibacterial Market to Double in Size
    • 11.13.1. Brazilian Market to Be Driven by Drug Resistance
  • 11.14. Russia: TB Prevalence to Stimulate Antibiotic Sales-Forecast 2019-2029

12. Leading Companies in the Antibacterial Drugs Market

  • 12.1. Pfizer Inc.
    • 12.1.1. Overview
    • 12.1.2. Financials
    • 12.1.3. Pipeline Portfolio
    • 12.1.4. Key Developments
  • 12.2. Novartis AG
    • 12.2.1. Overview
    • 12.2.2. Financials
    • 12.2.3. Pipeline Portfolio
    • 12.2.4. Key Developments
  • 12.3. Merck & Co. Inc.
    • 12.3.1. Overview
    • 12.3.2. Financials
    • 12.3.3. Product Portfolio
    • 12.3.4. Key Developments
  • 12.4. GlaxoSmithKline PLC
    • 12.4.1. Overview
    • 12.4.2. Financials
    • 12.4.3. Product Portfolio
    • 12.4.4. Key Developments
  • 12.5. BioVersys AG
    • 12.5.1. Overview
    • 12.5.2. Pipeline Portfolio
    • 12.5.3. Key Developments
  • 12.6. AstraZeneca PLC
    • 12.6.1. Overview
    • 12.6.2. Financials
    • 12.6.3. Pipeline Portfolio
    • 12.6.4. Key Developments
  • 12.7. Allecra Therapeutics GmbH
    • 12.7.1. Overview
    • 12.7.2. Pipeline Portfolio
    • 12.7.3. Key Developments
  • 12.8. Adenium Biotech ApS
    • 12.8.1. Overview
    • 12.8.2. Pipeline Portfolio
  • 12.9. Bayer AG
    • 12.9.1. Overview
    • 12.9.2. Financials
    • 12.9.3. Product Portfolio
  • 12.10. Eli Lilly and Company
    • 12.10.1. Overview
    • 12.10.2. Financials
    • 12.10.3. Pipeline Portfolio

13. Antibacterials R&D Pipeline Review, 2018

  • 13.1. Gram-Positive vs. Gram-Negative
  • 13.2. Pipeline Dominated by Small Molecule Drugs
  • 13.3. Some of the Leading Phase I Drug Candidates
    • 13.3.1. Nemiralisib(GlaxoSmithKline plc)
    • 13.3.2. Piperacillin/AAI101(Allecra Therapeutics GmbH
    • 13.3.3. MEDI3502(AstraZeneca plc)
    • 13.3.4. PF-06760805(Pfizer, Inc.)
    • 13.3.5. GSK3335065(GlaxoSmithKline plc)
  • 13.4. Some of Leading Phase II Drug Candidates
    • 13.4.1. Cefepime/AAI101(Allecra Therapeutics GmbH)
    • 13.4.2. Gepotidacin(GlaxoSmithKline plc)
    • 13.4.3. GSK3536852A(GlaxoSmithKline plc)
    • 13.4.4. QBW251(Novartis AG)
    • 13.4.5. GSK2982772(GlaxoSmithKline plc)
  • 13.5. Some of the Leading Phase III Drug Candidates
    • 13.5.1. V114(Merck & Co., Inc.)
    • 13.5.2. ZERBAXA(Merck & Co., Inc.)
    • 13.5.3. PT010(AstraZeneca plc)

14. Qualitative Analysis of the Antibacterial Industry and Market, 2019-2029

  • 14.1. SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
  • 14.2. STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
    • 14.2.1. Social Factors
    • 14.2.2. Technological Developments
    • 14.2.3. Economic Pressures
    • 14.2.4. Political Issues
  • 14.3. Market is Well Established and Demand Will Remain Strong
  • 14.4. High Prevalence of Bacterial Infection Worldwide
  • 14.5. Worldwide Demand for Antibacterials
  • 14.6. Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
  • 14.7. Cutting into a Saturated Market
  • 14.8. Superior Benefit over Generics?
  • 14.9. Resistance-Nature's Patent Expiry
  • 14.10. Acute Treatment Limits Commercial Potential
  • 14.11. Did Big Pharma Back Away from Antibacterial Drugs?
  • 14.12. Resistance Will Continue to Present New Targets
  • 14.13. First Biologic Antibacterials
  • 14.14. Potential for Smaller Firms to Capitalise
  • 14.15. Developing Preventative Vaccines Rather Than Treatments
  • 14.16. Antibacterial Stewardship Reduces Usage
  • 14.17. Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
    • 14.17.1. Therapeutic Success in European Clinical Trials
    • 14.17.2. Primary End Points in FDA Guidelines
  • 14.18. Reduction in Hospital Infection Rates-Reducing Demand for Antibacterial Drugs
  • 14.19. Enticing Antibacterial Drug Discovery-Push and Pull Incentives
    • 14.19.1. GAIN act: Post-Development Pull Incentives in the US
    • 14.19.2. ADAPT-Building on the GAIN act
    • 14.19.3. EMA Update Guideline-Streamlining Clinical Trials in the EU
    • 14.19.4. Push Incentives for Antibacterial Drug Discovery with Public Funding
    • 14.19.5. IMI: Public-Private Collaboration with GSK and AstraZeneca
    • 14.19.6. Public Finance Pumping Money into Antibacterial Development

15. Antibacterial Drugs Market 2019-2029: Conclusions

  • 15.1. Three Blockbuster Antibacterials in 2018-Leading Brands
  • 15.2. The Leading Branded Antibacterial Drugs in 2029
  • 15.3. Stemming the Tide of Antibacterial Drug Resistance
  • 15.4. The Changing Face of Antibacterial Clinical Development

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top
전화 문의
F A Q